v3.26.1
EQUITY (Tables)
 9 Months Ended
Mar. 31, 2026
Equity [Abstract]  
SCHEDULE OF WARRANTS OUTSTANDING

The remaining outstanding warrants as of March 31, 2026 are:

     

  

Warrants

Outstanding

  

Exercise

Price

  

Expiration

Date

            
July 2021 IPO   87,500   $7.00   June 2026
November 2021 SPA   481,000   $1.75   November 2026
November 2021 SPA   169,000   $1.75   May 2027
Total   737,500         
SCHEDULE OF STOCK OPTION FAIR VALUE ASSUMPTION

Stock options have been recorded at their fair value. The Black-Scholes option-pricing model assumptions used to value the issuance of stock options under the Plan for the specific periods below are noted in the following table:

     

   2026   2025   2026   2025 
   For the Three Months Ended
March 31,		   For the Nine Months Ended
March 31,		 
   2026   2025   2026   2025 
Weighted average expected terms (in years)   6.5    5.6    6.2    5.6 
Weighted average expected volatility   86.5%   125.4%   121.0%   121.4%
Weighted average risk-free interest rate   3.9%   4.4%   4.0%   4.3%
Expected dividend yield   0.0%   0.0%   0.0%   0.0%
SUMMARY OF STOCK OPTION ACTIVITY

The following is a summary of the Company’s stock option activity for the nine months ended March 31, 2026 and 2025, excluding the executive Target Options:

      

       Weighted Average     
           Remaining     
       Exercise   Contractual   Intrinsic 
   Options   Price   Term (Yrs)   Value 
Outstanding as of July 1, 2025   2,766,206   $3.37    5.6   $    - 
Options granted   240,000    2.15    9.5    - 
Options exercised   -    -    0.0    - 
Options forfeited / cancelled   (387,778)   3.67    5.4    - 
Outstanding as of March 31, 2026   2,618,428   $3.22    5.2   $- 
Exercisable as of March 31, 2026   2,086,809   $3.39    4.6   $- 
 
       Weighted Average     
           Remaining     
       Exercise   Contractual   Intrinsic 
   Options   Price   Term (Yrs)   Value 
Outstanding as of July 1, 2024   3,643,880   $3.95    6.5   $- 
Options granted   521,801    2.37    9.6    31,928 
Options exercised   (35,600)   2.50    2.1    - 
Options forfeited / cancelled   (1,180,125)   4.55    6.9    7,429 
Outstanding as of March 31, 2025   2,949,956   $3.46    6.0   $- 
Exercisable as of March 31, 2025   1,874,221   $3.78    4.8   $- 

 
SCHEDULE OF STOCK OPTION BASED EXPENSE

The Company’s stock option-based expense for the three and nine months ended March 31, 2026 and 2025 consisted of the following:

      

                 
   For the Three Months Ended   For the Nine Months Ended 
   March 31,   March 31, 
   2026   2025   2026   2025 
Stock option-based expense:                    
Research and development expenses  $49,600   $50,245   $133,296   $171,855 
General and administrative expenses   79,420    81,363    301,837    303,206 
Sales and marketing expenses   9,690    6,803    43,903    73,338 
Board option expense   -    102,235    204,470    127,154 
Total  $138,710   $240,646   $683,506   $675,553